Complex probiotic composition and method for improving exercise performance of subject with low intrinsic aerobic exercise capacity
US-2024139262-A1 · May 2, 2024 · US
US9314047B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9314047-B2 |
| Application number | US-81710206-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 28, 2006 |
| Priority date | Feb 28, 2005 |
| Publication date | Apr 19, 2016 |
| Grant date | Apr 19, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A composition comprising Bifidobacterium breve , a non-digestible saccharide A and a non-digestible saccharide B, optionally combined with Lactobacillus paracasei and the use of said composition for the treatment and/or prevention of gastro-intestinal disorder, immune disorder and/or endocrine disorder.
Opening claim text (preview).
The invention claimed is: 1. An infant formula composition having a viscosity between 1 and 6 mPa·s and a caloric density between 10 and 250 kcal per 100 ml comprising: a. Bifidobacterium breve; b. a first non-digestible saccharide having a degree of polymerisation between 2 and 8 and at least 60 mol % of the total monosaccharide units of the first non-digestible saccharide are fructose; and c. a second non-digestible saccharide having a degree of polymerisation between 8 and 100 and at least 60 mol % of the total monosaccharide units of the second non-digestible saccharide are fructose; wherein i. the average degree of polymerisation of the first non-digestible saccharide is at least 5 monosaccharide units lower than the average degree of polymerisation of the second non-digestible saccharide; ii. the concentration of the first saccharide is between 50 mg and 2 g per 100 ml and the concentration of the second saccharide is between 5 mg and 1 g per 100 ml; and iii. a non-digestible saccharide is a saccharide that is not digested in the upper intestinal tract of a human infant. 2. The infant formula composition according to claim 1 wherein the viscosity is 2±0.2 mPa·s. 3. The infant formula composition according to claim 1 , wherein the weight ratio between the first non-digestible saccharide and the second non-digestible saccharide is between 4 and 24. 4. The infant formula composition according to claim 1 further comprising Lactobacillus paracasei. 5. The infant formula composition according to claim 1 , wherein the first and second non-digestible saccharide each comprises at least 75 mol % fructose units based on the total monosaccharide units of first and second non-digestible saccharide. 6. The infant formula composition according to claim 1 comprising 10 2 to 10 13 colony forming units of Bifidobacterium breve per gram of dry weight of the composition. 7. The infant formula composition according to claim 1 , wherein: (i) 5 to 16 percent of the total energy of the composition is derived from protein, (ii) 30 to 60 percent of the total energy of the composition is derived from fat, and (iii) 25 to 75 percent of the total energy of the composition is derived from carbohydrates. 8. The infant formula composition according to claim 1 comprising between 0.1 and 2 g of the first non-digestible saccharide per 100 ml and between 10 mg and 1 g of the second non-digestible saccharide per 100 ml. 9. The infant formula composition according to claim 1 comprising at least 0.75 mg nucleotides per 100 ml. 10. The infant formula composition according to claim 4 , wherein: (i) 5 to 16 percent of the total energy of the composition is derived from protein, (ii) 30 to 60 percent of the total energy of the composition is derived from fat, and (iii) 25 to 75 percent of the total energy of the composition is derived from carbohydrates. 11. A method for providing nutrition to an infant comprising administering to the infant a nutritional composition having a viscosity between 1 and 6 mPa·s and a caloric density between 10 and 250 kcal per 100 ml and comprising: a. Bifidobacterium breve; b. a first non-digestible saccharide having a degree of polymerisation between 2 and 8 and at least 60 mol % of the total monosaccharide units of the first non-digestible saccharide are fructose; and c. a second non-digestible saccharide having a degree of polymerisation between 8 and 100 and at least 60 mol % of the total monosaccharide units of the second non-digestible saccharide are fructose; wherein the average degree of polymerisation of the first non-digestible saccharide is at least 5 monosaccharide units lower than the average degree of polymerisation of the second non-digestible saccharide and the concentration of the first saccharide is at least 50 mg per 100 ml and the concentration of the second saccharide is at least 5 mg per 100 ml. 12. The infant formula composition according to claim 8 , comprising between 0.1 and 2 g per 100 ml of the first non-digestible saccharide and between 10 mg and 1 g per 100 ml of the second non-digestible saccharide. 13. The infant formula composition according to claim 12 , comprising between 0.5 and 2 g per 100 ml of the first non-digestible saccharide and between 50 mg and 1 g per 100 ml of the second non-digestible saccharide.
Drugs for disorders of the endocrine system · CPC title
Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title
Drugs for immunological or allergic disorders · CPC title
Immunomodulators · CPC title
Nutrients, e.g. vitamins, minerals · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.